Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab.
Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab.
复制标题
DOI：
10.1016/j.jneuroim.2021.577788
复制
发表时间：
2022-01-15
影响因子：
3.3
通讯作者：
Habek M
中科院分区：
文献类型：
--
作者：
Adamec I;Rogić D;Penz MG;Braun C;Habek M
To report clinical outcome, development of humoral and T-cell mediated immunity in convalescent COVID-19 people with multiple sclerosis (pwMS) treated with ofatumumab in the ALITHIOS study from a single center. Testing for SARS-Cov2 IgG antibodies was performed on two occasions with at least three months apart between the two testing. During the second antibody testing, interferon-γ ELISpot was used to assess cellular immunity. All four subjects had mild COVID-19 infection without any sequelae. In all subjects except subject 2, COVID-19 was confirmed with PCR. Subjects 1, 2 and 4 had normal levels of IgM and IgG without measurable counts of CD19 cells prior to COVID-19. Subject 3 administered the last dose of ofatumumab 24 days prior to COVID-19 symptoms, but had a gap of 28 weeks of ofatumumab application beforehand due to low IgM levels. Subject 4 received COVID-19 vaccinations before second testing, so second testing and T-cell immunity testing were not performed. Subjects who were CD19 depleted did not had measurable levels of SARS-Cov2 IgG antibodies. Subject 3 had first and second SARS-COV2 titer of 118 U/ml and > 250 U/ml, respectively. All three pwMS showed T cell immunity against SARS-CoV-2. Quotient of basal spots divided by interferon-γ secreting spot forming units were 4, 8 and 14.7 SI in subjects 1, 2 and 3, respectively (>3 considered reactive). While no antibody response was observed in pwMS who were CD19+ lymphocyte depleted, T cell immunity against SARS-CoV-2 was observed in all three pwMS treated with ofatumumab.
登录
查看更多内容
影响因子：
158.5
作者：
Hauser, Stephen L.;Bar-Or, Amit;Kappos, Ludwig
通讯作者：
Kappos, Ludwig
影响因子：
5.8
作者：
Sormani, Maria Pia;Schiavetti, Irene;Salvetti, Marco
通讯作者：
Salvetti, Marco
影响因子：
11.2
作者：
Sormani MP;De Rossi N;Schiavetti I;Carmisciano L;Cordioli C;Moiola L;Radaelli M;Immovilli P;Capobianco M;Trojano M;Zaratin P;Tedeschi G;Comi G;Battaglia MA;Patti F;Salvetti M;Musc-19 Study Group
通讯作者：
Musc-19 Study Group
影响因子：
4
作者：
Stastna D;Menkyova I;Drahota J;Mazouchova A;Adamkova J;Ampapa R;Grunermelova M;Peterka M;Recmanova E;Rockova P;Rous M;Stetkarova I;Valis M;Vachova M;Woznicova I;Horakova D
通讯作者：
Horakova D
影响因子：
29
作者：
Brill, Livnat;Rechtman, Ariel;Vaknin-Dembinsky, Adi
通讯作者：
Vaknin-Dembinsky, Adi